Among these potential therapeutic targets, the establishment of anti-IL-6 and TNF-α antibodies, as well as Janus kinase (JAK) inhibitor therapies for rheumatoid arthritis, have been the most successful. Here, TNF is linked to rheumatoid arthritis.